Embecta (NASDAQ:EMBC) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Embecta (NASDAQ:EMBC) from a buy rating to a strong-buy rating in a report issued on Saturday.

EMBC has been the topic of a number of other reports. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Embecta in a report on Wednesday, January 21st. BTIG Research reissued a “buy” rating and set a $25.00 target price on shares of Embecta in a report on Friday, February 6th. One investment analyst has rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $18.50.

Embecta Stock Up 1.8%

Shares of EMBC stock opened at $9.23 on Friday. Embecta has a 12-month low of $8.81 and a 12-month high of $15.55. The company has a market capitalization of $546.60 million, a PE ratio of 3.89 and a beta of 1.10. The firm has a 50 day moving average price of $11.03 and a two-hundred day moving average price of $12.71.

Embecta (NASDAQ:EMBC) last posted its earnings results on Thursday, February 5th. The company reported $0.71 EPS for the quarter, beating the consensus estimate of $0.67 by $0.04. The company had revenue of $261.20 million for the quarter, compared to the consensus estimate of $258.07 million. Embecta had a negative return on equity of 26.66% and a net margin of 12.92%.The firm’s revenue for the quarter was down .3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.65 earnings per share. Embecta has set its FY 2026 guidance at 2.800-3.00 EPS. As a group, research analysts expect that Embecta will post 2.85 EPS for the current year.

Embecta Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 17th. Investors of record on Friday, February 27th will be paid a $0.15 dividend. This represents a $0.60 annualized dividend and a dividend yield of 6.5%. The ex-dividend date is Friday, February 27th. Embecta’s payout ratio is 25.32%.

Hedge Funds Weigh In On Embecta

A number of hedge funds have recently added to or reduced their stakes in EMBC. Alpine Global Management LLC acquired a new position in Embecta in the 4th quarter valued at $178,000. River Road Asset Management LLC grew its holdings in shares of Embecta by 5.3% during the 4th quarter. River Road Asset Management LLC now owns 3,416,401 shares of the company’s stock worth $40,587,000 after purchasing an additional 171,194 shares in the last quarter. Pacer Advisors Inc. increased its position in shares of Embecta by 49.3% in the fourth quarter. Pacer Advisors Inc. now owns 16,526 shares of the company’s stock worth $196,000 after purchasing an additional 5,460 shares during the period. State of Tennessee Department of Treasury increased its position in shares of Embecta by 23.9% in the fourth quarter. State of Tennessee Department of Treasury now owns 53,290 shares of the company’s stock worth $633,000 after purchasing an additional 10,263 shares during the period. Finally, Mackenzie Financial Corp raised its stake in Embecta by 34.0% in the fourth quarter. Mackenzie Financial Corp now owns 135,085 shares of the company’s stock valued at $1,627,000 after purchasing an additional 34,240 shares in the last quarter. Institutional investors own 93.83% of the company’s stock.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.